Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Studie av NX-5948 i kombination med andra agenser hos vuxna med B-cellsmaligniteter

13 november 2026 uppdaterad av: Nurix Therapeutics, Inc.

En öppen, multricenter Fas 1b/2-studie för att utvärdera säkerheten och effekten av NX-5948 i kombination med andra läkemedel hos vuxna med B-cellsmaligniteter

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Studieöversikt

Detaljerad beskrivning

Bexobrutideg is an investigational drug designed to target a protein called Bruton tyrosine kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. Bexobrutideg is a protein degrader, which means it finds and destroys the BTK in the cell. Venetoclax, rituximab, and obinutuzumab are approved medications that are used to treat CLL/SLL.

The study will look at:

  • How safe bexobrutideg is for patients with CLL or SLL when taken with these other treatments
  • The effects of bexobrutideg in the body when taken with these other treatments
  • How well bexobrutideg treats CLL or SLL when taken with these other treatments

Studietyp

Interventionell

Inskrivning (Beräknad)

150

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • California
      • Irvine, California, Förenta staterna, 92618
        • Har inte rekryterat ännu
        • City of Hope Orange County Lennar Foundation Cancer Center
    • Colorado
      • Aurora, Colorado, Förenta staterna, 80012
        • Rekrytering
        • Rocky Mountain Cancer Centers
    • Florida
      • Coral Gables, Florida, Förenta staterna, 33146
        • Har inte rekryterat ännu
        • University of Miami
    • Kansas
      • Kansas City, Kansas, Förenta staterna, 66160
        • Har inte rekryterat ännu
        • University of Kansas Cancer Center
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89169
        • Har inte rekryterat ännu
        • Comprehensive Cancer Centers of Nevada
    • New Jersey
      • Belleville, New Jersey, Förenta staterna, 07109
        • Har inte rekryterat ännu
        • New Jersey Cancer Care
    • Oregon
      • Eugene, Oregon, Förenta staterna, 97401
        • Rekrytering
        • Oncology Associates of Oregon
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Förenta staterna, 15232
        • Rekrytering
        • UPMC Hillman Cancer Center
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37203
        • Rekrytering
        • SCRI Oncology Partners
    • Texas
      • Tyler, Texas, Förenta staterna, 75702
        • Rekrytering
        • Texas Oncology - Northeast

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Adequate organ and bone marrow function
  • Measurable disease by computed tomography (CT) per iwCLL
  • For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
  • For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria
  • Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate

Key Exclusion Criteria:

  • Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
  • Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
  • Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
  • Use of systemic corticosteroids (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
  • Previously treated with a BTK degrader
  • Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment
  • Known central nervous system (CNS) lymphoma or leukemia
  • Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
  • Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment

Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: NX-5948 + venetoklax

Administered orally once daily as a capsule

Andra namn:
  • bexobrutideg

Administered orally once daily as a tablet per prescribing information

Experimentell: NX-5948 + venetoclax + rituximab

Administered orally once daily as a capsule

Andra namn:
  • bexobrutideg

Administered orally once daily as a tablet per prescribing information

Administered as an intravenous (IV) infusion per prescribing information

Experimentell: NX-5948 + venetoklax + obinutuzumab

Administered orally once daily as a capsule

Andra namn:
  • bexobrutideg

Administered orally once daily as a tablet per prescribing information

Administered as an IV infusion per prescribing information

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Antal deltagare med behandlingsrelaterade biverkningar
Tidsram: Upp till cirka 7 år
Upp till cirka 7 år

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Objective response rate as determined by investigator
Tidsram: Up to approximately 7 years

The percentage of participants with response as determined according to 2018 iwCLL guidelines; response includes complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), PR with lymphocytosis (PR-L), and nodular PR

Up to approximately 7 years
Duration of response as determined by investigator
Tidsram: Up to approximately 7 years

Time from the date of the first response to the date of documented progressive disease or death due to any cause, whichever is earlier

Up to approximately 7 years
Progression-free survival as determined by investigator
Tidsram: Up to approximately 7 years

Time from the date of the first dose of study drug to the date of documented progressive disease or death due to any cause, whichever is earlier

Up to approximately 7 years
Complete response rate as determined by investigator
Tidsram: Up to approximately 7 years

The percentage of participants with CR or CRi as determined according to 2018 iwCLL guidelines; includes CR + CRi for participants with CLL.

Up to approximately 7 years
Time to response as determined by investigator
Tidsram: Up to approximately 7 years

Time from the start date of study treatment to the date of the first assessment of a response

Up to approximately 7 years
Overall survival
Tidsram: Up to approximately 7 years

Time from the start date of study treatment to the date of death from any cause

Up to approximately 7 years
Pharmacokinetic profile of NX-5948
Tidsram: Up to approximately 1 year

NX-5948 concentrations in blood samples

Up to approximately 1 year
Pharmacokinetic profile of venetoclax
Tidsram: Up to approximately 1 year

Venetoclax concentrations in blood samples

Up to approximately 1 year
Change from baseline in Global Health Status/Quality of Life on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30)
Tidsram: Baseline and up to approximately 27 months

Percentage of participants with a clinically meaningful change from baseline using the EORTC QLQ-C30 questionnaire to assess the overall quality of life

Baseline and up to approximately 27 months
Change from baseline in European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)
Tidsram: Baseline and up to approximately 27 months

Percentage of participants with a clinically meaningful change from baseline using the EQ-5D-5L questionnaire to assess health outcomes

Baseline and up to approximately 27 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Study Director, Nurix Therapeutics, Inc.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

30 september 2026

Primärt slutförande (Beräknad)

1 maj 2033

Avslutad studie (Beräknad)

1 maj 2033

Studieregistreringsdatum

Först inskickad

2 april 2026

Först inskickad som uppfyllde QC-kriterierna

2 april 2026

Första postat (Faktisk)

9 april 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 november 2026

Senast verifierad

1 november 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera